Author:
Meade S.,Gaunt P.,Hartley A.,Robinson M.,Harrop V.,Cashmore J.,Wagstaff L.,Babrah J.,Bowden S.J.,Mehanna H.,Sanghera P.
Funder
Queen Elizabeth Hospital Birmingham Charities
Subject
Radiology Nuclear Medicine and imaging,Oncology
Reference40 articles.
1. Human papillomavirus and survival of patients with oropharyngeal cancer;Ang;N Eng J Med,2010
2. Mehanna H, Dunn J, McConkey C, Hartley A, Robinson M, Kong A, et al. De-ESCALaTE HPV: determination of epidermal growth factor receptor-inhibitor (cetuximab) versus standard chemotherapy (cisplatin) early and late toxicity events in human papillomavirus-positive oropharyngeal squamous cell carcinoma. deescalate@warwick.ac.uk. ISRCTN identifier ISRCTN33522080. https://doi.org/10.1186/ISRCTN33522080.
3. Trotti A, Gillison M. RTOG 1016 phase III trial of radiotherapy plus cetuximab versus chemoradiotherapy in HPV-associated oropharynx cancer. www.rtog.org. ClinicalTrials.gov identifier NCT01302834.
4. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients;Pignon;Radiother Oncol,2009
5. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis;Bourhis;Lancet,2006
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献